Phaseolinone is a natural product isolated from the seeds of the common bean (Phaseolus vulgaris). It exhibits potent antifungal activity against a range of fungal species, including Fusarium, Aspergillus, and Botrytis. Phaseolinone has also shown activity against plant pathogens, such as the bacterial blight pathogen Xanthomonas campestris pv. glycines. The compound is a phytoalexin, meaning it is produced by plants in response to stress, such as infection. The biosynthesis of phaseolinone involves a complex pathway that includes the enzyme chalcone synthase. Phaseolinone is studied for its potential as a natural fungicide and for its role in plant defense mechanisms. '
phaseolinone: RN from toxlit 8/88; isolated from Macrophomina phaseolina; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 114980 |
| MeSH ID | M0158186 |
| Synonym |
|---|
| naphth(1,2-b)oxiren-2(1ah)-one, 4,5,6,7,7a,7b-hexahydro-6-hydroxy-1a-((2r)-2-(hydroxymethyl)oxiranyl)-7,7a-dimethyl-, (1as,6r,7r,7ar,7br)- |
| ccris 1276 |
| phaseolinone |
| 85431-61-4 |
| (+)-phaseolinone |
| (1as,6r,7r,7ar,7br)-6-hydroxy-1a-[(2r)-2-(hydroxymethyl)oxiran-2-yl]-7,7a-dimethyl-5,6,7,7b-tetrahydro-4h-naphtho[1,2-b]oxiren-2-one |
| oi28985toj , |
| unii-oi28985toj |
| phaseolinone, (+)- |
| (1as,6r,7r,7ar,7br)-4,5,6,7,7a,7b-hexahydro-6-hydroxy-1a-((2r)-2-(hydroxymethyl)oxiranyl)-7,7a-dimethylnaphth(1,2-b)oxiren-2(1ah)-one |
| Q27285663 |
| 6-hydroxy-1a-[2-(hydroxymethyl)oxiran-2-yl]-7,7a-dimethyl-4,5,6,7,7a,7b-hexahydronaphtho[1,2-b]oxiren-2(1ah)-one |
| DTXSID901005947 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.77) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||